If they could find the right partner for the drug, which means mutiple indications in different lines as both mono and combination therapies, and for right price, sure they should take it. If not, it's not bad idea to go alone in this case at all.
1. NKTR, as a company in inflection point, could either follow identifying new drug then partner, safer strategy of the past or make bolder move to develop lower risk drug when they have the financial means to do it.
2. NKTR102 is based on a known/approved molecule, so the risk is much lower than a brand new drug with novel mechanism. Celgene and Abraxis are good examples to follow.
The mistake the management made was to build partner expectation first, but failed to deliver. I would have lowered partner expectation first, saying only if right partner and price came along. So, I am happy they put their number 1 priority on NKTR102 on OC and BC at this point. Once the pivotal trials are initiated, they can do other things. For company NKTR's size, you shouldn't try to do too much at the same time.
Market Data 
Markets 
AI
